Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab
Only limited data on laboratory parameter dynamics and safety under prolonged biologic treatment in a “real-world” scenario are available for recommendations on screening and monitoring. This study is a retrospective analysis of routine parameter dynamics and laboratory adverse events (L...
Main Authors: | Jochen H. Hoffmann, Christian Knoop, Alexander H. Enk, Eva N. Hadaschik |
---|---|
Format: | Article |
Language: | English |
Published: |
Society for Publication of Acta Dermato-Venereologica
2017-03-01
|
Series: | Acta Dermato-Venereologica |
Subjects: | |
Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2644
|
Similar Items
-
The cost of biologics for psoriasis is increasing
by: Judy Cheng, et al.
Published: (2014-12-01) -
Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab
by: Chiharu Tateishi,, et al.
Published: (2015-07-01) -
Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis
by: Ahmed I. Mourad, et al.
Published: (2021-03-01) -
Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
by: Ting-Shun Wang, et al.
Published: (2013-03-01) -
Systemic Psoriasis Treatment at an Early Age (Part II): Issues of Biological Therapy
by: L. S. Namazova-Baranova, et al.
Published: (2018-02-01)